Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. is a pharmaceutical development company focused on creating and potentially selling treatments derived from active pharmaceutical ingredients that are already approved. The company's main focus is on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. Its business strategy involves repurposing established drug substances, supported by distinct formulation, regulatory, and intellectual property approaches. This aims to streamline development and increase commercial value. The company's primary program uses itraconazole, an antifungal agent approved by the FDA, for the long-term management of basal cell carcinomas in patients with BCCNS. Inhibitor Therapeutics views BCCNS as a significant initial target because it is a serious, lifelong condition requiring frequent procedures, has few lasting treatment options, and involves a patient population managed by specialists. Currently, the company's business model primarily focuses on advancing this program through regulatory development and potential strategic transactions, such as licensing, partnerships, or divestment. In February 2026, with assistance from Frameshift Management, Inc., Inhibitor Therapeutics submitted a formal meeting request and briefing materials to the U.S. Food and Drug Administration (FDA) concerning its proposed development path for itraconazole in BCCNS. The FDA granted this request as a Type C meeting, with written responses anticipated in May 2026. The company plans to ask the FDA for a videoconference instead of written responses. The meeting request asks the FDA about topics including the suitability of per-lesion response as a primary efficacy endpoint in BCCNS, the adequacy of the existing HP2001 efficacy and safety data, and the potential use of expedited programs and a 505(b)(2) new drug application pathway. Inhibitor Therapeutics has also hired Avior Bio, Inc. to create a proprietary micronized/amorphous itraconazole formulation for its BCCNS program. Formulation development is complete, and the company is conducting pharmacokinetic studies to compare the Avior formulation to itraconazole formulations previously used in clinical settings.